We use cookies for a better user experience. Read our Privacy Policy

I Agree

Oncology Biosimilars Market

Oncology Biosimilars Market (Drug Class - G-CSF, Monoclonal Antibodies, and Hematopoietic Agents; Disease Indication - Breast Cancer, Non-small Cell Lung Cancer, Colorectal Cancer, Neutropenia, and Blood Cancer (Leukemia and Non-Hodgkin Lymphoma); and Distribution Channel - Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

The need to differentiate active and inactive components in drugs has helped in popularising oncology biosimilars. Research analysts can differentiate drugs on the basis of their inactive components, even when the reference component or drugs remains the same. The importance of oncology biosimilars that can have different actions on cancers of various types has helped in reconciling the growth dynamics of the market. The tremendous relevance of biosimilar therapies for cancer has also helped researchers in emphasizing on the importance of oncology biosimilars.

The Food and Drugs Administration (FDA) in the US has been at the forefront of growth within the global oncology biosimilars market. Approval of several biosimilars by the FDA have been helpful for research entities and organizations. Post 2015, FDA has been actively approving oncology biosimilars, a trend that is expected to gather momentum in the times to follow. filgrastim-sndz (Zarxio) and Bevacizumab-awwb (Mvasi) are two important biosimilars that were lately approved by the FDA. It would be interesting to see the impact of increased pace of approvals on market maturity.

In this preview, several trends, opportunities, and segments pertaining the global oncology biosimilars market have been discussed. The presence of a seamless medical industry that focuses on developing treatment lines for cancer is an important consideration from the standpoint of market analysis. In addition to this, several University scholars have tasted success in developing possible treatment lines for cancer. TMR predicts that the global oncology biosimilars market would grow at a humongous CAGR of 27.5% over the period between 2017 and 2025. The voluminous growth rate can be attributed to investments made in cancer research and analysis. Furthermore, the total worth of the global oncology biosimilars market is set to touch US$17,478.2 mn by 2025-end.

oncology biosimilars market

Treatment of Breast Cancer Takes Center Stage Medicine

The global oncology biosimilars market consists of a complex of net of end-uses and applications. Based on disease indication, oncology biosimilars can be segmented into breast cancer, colorectal cancer, neutropenia, lung cancer, and blood cancer. Amongst these, the demand for oncology biosimilars in treating and understanding breast cancer has increased by a dramatic chase. Besides, rising incidence of leukaemia has played to the advantage of the market vendors.

Rising incidence of various types of cancers plays an integral role in driving sales across the global oncology biosimilars market. Clinical research related to oncology has gathered momentum in recent times, and this trend has reflected in the development of several distinct drugs. Research related to leukaemia has especially attracted increased attention from medical researchers. Considering the factors mentioned above, it is safe to predict that the global oncology biosimilars market would gain momentum in the years to follow. Advancements in drug development and analysis of active ingredients in drugs is also an important consideration from the perspective of market growth. Biologic drugs are gradually becoming an important component of the pharmaceutical industry. These drugs are poised to account for a major share of drugs mix produced by the industry.

Regional Dynamics of the Global Oncology Biosimilars Market

On the basis of regions, the global oncology biosimilars market can be segmented into Latin America, North America, Europe, Asia Pacific, and the Middle East and Africa. Investments in cancer research, especially across the UK, are central to the idea of market growth in Europe. Recently, scholars from Cardiff University discovered a potential cure for bodily cancers. The North America oncology biosimilars market is set to expand as new research centers and laboratories emerge in the region.

Some of the leading vendors in the global oncology biosimilars market are Dr. Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., and Sandoz International GmbH.

Booming Cases of Cancer around the World to Accelerate the Growth Opportunities across the Oncology Biosimilars Market

The oncology biosimilars market is expected to witness a considerable growth-share owing to the rising number of cancer cases across the globe. The increasing number of cancer cases around the world will serve as a vital growth generator for the oncology biosimilars market.

  • According to the World Health Organization (WHO), cancer is the second leading cause of death across the globe. The WHO data estimates the number of deaths at 9.6 mn in 2018 due to cancer. These statistics highlight the need for controlling the number of deaths due to cancer on priority. Thus, this factor will invite considerable growth opportunities for the oncology biosimilars market.
  • Biosimilars are proven biological drugs extensively similar to the original drug on the basis of potency, safety, and purity. They are cost-effective but have the same quality as the original. Oncology biosimilars are utilized as therapeutic, diagnostic, or preventive agents for treating varied cancer types and symptoms. The functions of the oncology biosimilars make them the first choice for many individuals suffering from cancer eventually increasing the growth rate.
  • Research and development activities form an important part of the growth trajectory of the oncology biosimilars market. The players invest in these activities for exploring varied formulations that assist in increasing the revenues. The players also indulge in strategic collaborations, which further help in influencing the growth prospects of the oncology biosimilars market to a substantial extent.
  • The COVID-19 pandemic has affected the pharmaceutical industry considerably. The nationwide enforcement of lockdowns across various countries led to supply chain disruptions. Limited access to clinical sites due to extensive research activities related to COVID-19 is negatively affecting the growth of the oncology biosimilars market to a great extent.
  • However, as the pharmaceutical industry was exempt from the lockdown restrictions, the oncology biosimilars market has manged to retain the growth of the oncology biosimilars market.

Interested in this report?
Get a FREE sample now!

Get Free Sample

*Get Sample Report (PDF) sent to your email within minutes

Section 01 Preface
1.1 Market Definition and Scope
1.2 Research Highlights

Section 02 Assumptions and Research Methodology
2.1 Assumptions & Acronyms Used
2.2 Research Methodology

Section 03 Executive Summary: Global Oncology Biosimilars Market
3.1 Executive Summary
3.2 Market Opportunity Map
3.3 Market Overview
3.4 Key Industry Developments
3.5 Global Oncology Biosimilars Market Size (US$ Mn) Forecast, 2015–2025
3.6 Global Oncology Biosimilars Market Outlook

Section 04 Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunity
4.4 Key Trends

Section 05 Porter’s Five Force Analysis

Section 06 Oncology Biosimilars: Key Molecules

Section 07 Biosimilars Market Snapshot

Section 08 Cancer Statistics

Section 09 Global Oncology Biosimilars Market Analysis and Forecasts, By Drug Class 
9.1 Introduction & Definition
9.2 Key Findings 
9.3 Global Oncology Biosimilars Market Value Share, by Drug Class, 2017 and 2025
9.4 Market Attractiveness By Drug Class 
9.5 Global Oncology Biosimilars Market Forecast, by Drug Class, 2015-2025
      9.5.1 G-CSF
      9.5.2 Monoclonal Antibody
      9.5.3 Hematopoietic Agents
9.6 Global Oncology Biosimilars Market Analysis, by Drug Class, 2015-2025
9.7 Key Trends

Section 10 Global Oncology Biosimilars Market Analysis and Forecasts, By Disease Indication 
10.1 Introduction & Definition
10.2 Key Findings 
10.3 Global Oncology Biosimilars Market Value Share, by Disease Indication, 2017 and 2025
10.4 Market Attractiveness By Disease Indication
10.5 Global Oncology Biosimilars Market Forecast, by Disease Indication, 2015-2025
      10.5.1 Breast Cancer
      10.5.2 Non-Small Cell lung Cancer
      10.5.3 Blood Cancer
               10.5.3.1 Leukemia
                          10.5.3.1.1 Myeloid Leukemia
                          10.5.3.1.2 Chronic Lymphocytic Leukemia
                          10.5.3.1.3 Others
               10.5.3.2 Non-Hodgkin Lymphoma
      10.5.4 Colorectal Cancer
      10.5.5 Neutropenia
      10.5.6 Others
10.6 Global Oncology Biosimilars Market Analysis, by Disease Indication, 2015-2025
10.7 Key Trends

Section 11 Global Oncology Biosimilars Market Analysis and Forecasts, By Distribution Channel 
11.1 Introduction & Definition
11.2 Key Findings 
11.3 Global Oncology Biosimilars Market Value Share, by Distribution Channel, 2017 and 2025
11.4 Market Attractiveness By Distribution Channel
11.5 Global Oncology Biosimilars Market Forecast, by Distribution Channel, 2015-2025
      11.5.1 Hospital Pharmacy
      11.5.2 Online Pharmacy
      11.5.3 Retail Pharmacy
11.6 Global Oncology Biosimilars Market Analysis, by Distribution Channel, 2015-2025
11.7 Key Trends

Section 12 Global Oncology Biosimilars Market Analysis and Forecasts, By Region
12.1 Global Market Scenario
12.2 Global Oncology Biosimilars Market Value Share, by Region, 2017 and 2025
12.3 Global Oncology Biosimilars Market Attractiveness, by Region, 2017–2025
12.4 Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Region, 2015–2025
      12.4.1 North America 
      12.4.2 Europe 
      12.4.3 Asia Pacific 
      12.4.4 Rest of the World 

Section 13 North America Oncology Biosimilars Market Analysis and Forecast
13.1 North America Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015–2025
13.2 North America Oncology Biosimilars Market Value Share, by Country, 2017 and 2025
13.3 North America Oncology Biosimilars Market Attractiveness, by Country, 2017–2025
13.4 North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2015–2025
      13.4.1 U.S.
      13.4.2 Canada
13.5 North America Oncology Biosimilars Market Value Share, by Drug Class, 2017 and 2025
13.6 North America Oncology Biosimilars Market Attractiveness, by Drug Class, 2017–2025
13.7 North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
      13.7.1 G-CSF
      13.7.2 Monoclonal Antibody
      13.7.3 Hematopoietic Agents
13.8 North America Oncology Biosimilars Market Value Share, by Disease Indication, 2017 and 2025
13.9 North America Oncology Biosimilars Market Attractiveness, by Disease Indication, 2017–2025
13.10 North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
      13.10.1 Breast Cancer
      13.10.2 Non-Small Cell lung Cancer
      13.10.3 Blood Cancer
               13.10.3.1 Leukemia
                          13.10.3.1.1 Myeloid Leukemia
                          13.10.3.1.2 Chronic Lymphocytic Leukemia
                          13.10.3.1.3 Others
               13.10.3.2 Non-Hodgkin Lymphoma
      13.10.4 Colorectal Cancer
      13.10.5 Neutropenia
      13.10.6 Others
13.11 North America Oncology Biosimilars Market Value Share, by Distribution Channel, 2017 and 2025
13.12 North America Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2017–2025
13.13 North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
      13.13.1 Hospital Pharmacy
      13.13.2 Online Pharmacy
      13.13.3 Retail Pharmacy
13.14 Key Trends

Section 14 Europe Oncology Biosimilars Market Analysis and Forecast
14.1 Europe Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015–2025
14.2 Europe Oncology Biosimilars Market Value Share, by Country, 2017 and 2025
14.3 Europe Oncology Biosimilars Market Attractiveness, by Country, 2017–2025
14.4 Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2015–2025
      14.4.1 U.K.
      14.4.2 Germany
      14.4.3 France
      14.4.4 Italy
      14.4.5 Russia
      14.4.6 Spain
      14.4.7 Rest of Europe
14.5 Europe Oncology Biosimilars Market Value Share, by Drug Class, 2017 and 2025
14.6 Europe Oncology Biosimilars Market Attractiveness, by Drug Class, 2017–2025
14.7 Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
      14.7.1 G-CSF
      14.7.2 Monoclonal Antibody
      14.7.3 Hematopoietic Agents
14.8 Europe Oncology Biosimilars Market Value Share, by Disease Indication, 2017 and 2025
14.9 Europe Oncology Biosimilars Market Attractiveness, by Disease Indication, 2017–2025
14.10 Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
      14.10.1 Breast Cancer
      14.10.2 Non-Small Cell lung Cancer
      14.10.3 Blood Cancer
               14.10.3.1 Leukemia
                          14.10.3.1.1 Myeloid Leukemia
                          14.10.3.1.2 Chronic Lymphocytic Leukemia
                          14.10.3.1.3 Others
               14.10.3.2 Non-Hodgkin Lymphoma
      14.10.4 Colorectal Cancer
      14.10.5 Neutropenia
      14.10.6 Others
14.11 Europe Oncology Biosimilars Market Value Share, by Distribution Channel, 2017 and 2025
14.12 Europe Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2017–2025
14.13 Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
      14.13.1 Hospital Pharmacy
      14.13.2 Online Pharmacy
      14.13.3 Retail Pharmacy
14.14 Key Trends

Section 15 Asia Pacific Oncology Biosimilars Market Analysis and Forecast
15.1 Asia Pacific Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015–2025
15.2 Asia Pacific Oncology Biosimilars Market Value Share, by Country, 2017 and 2025
15.3 Asia Pacific Oncology Biosimilars Market Attractiveness, by Country, 2017–2025
15.4 Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2015–2025
      15.4.1 China
      15.4.2 India
      15.4.3 Japan
      15.4.4 Australia & New Zealand
      15.4.5 Rest of Asia Pacific
15.5 Asia Pacific Oncology Biosimilars Market Value Share, by Drug Class, 2017 and 2025
15.6 Asia Pacific Oncology Biosimilars Market Attractiveness, by Drug Class, 2017–2025
15.7 Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
      15.7.1 G-CSF
      15.7.2 Monoclonal Antibody
      15.7.3 Hematopoietic Agents
15.8 Asia Pacific Oncology Biosimilars Market Value Share, by Disease Indication, 2017 and 2025
15.9 Asia Pacific Oncology Biosimilars Market Attractiveness, by Disease Indication, 2017–2025
15.10 Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
      15.10.1 Breast Cancer
      15.10.2 Non-Small Cell lung Cancer
      15.10.3 Blood Cancer
               15.10.3.1 Leukemia
                          15.10.3.1.1 Myeloid Leukemia
                          15.10.3.1.2 Chronic Lymphocytic Leukemia
                          15.10.3.1.3 Others
               15.10.3.2 Non-Hodgkin Lymphoma
      15.10.4 Colorectal Cancer
      15.10.5 Neutropenia
      15.10.6 Others
15.11 Asia Pacific Oncology Biosimilars Market Value Share, by Distribution Channel, 2017 and 2025
15.12 Asia Pacific Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2017–2025
15.13 Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
      15.13.1 Hospital Pharmacy
      15.13.2 Online Pharmacy
      15.13.3 Retail Pharmacy
15.14 Key Trends

Section 16 Rest of the World Oncology Biosimilars Market Analysis and Forecast
16.1 Rest of the World Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015–2025
16.2 Rest of the World Oncology Biosimilars Market Value Share, by Country, 2017 and 2025
16.3 Rest of the World Oncology Biosimilars Market Attractiveness, by Country, 2017–2025
16.4 Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2015–2025
      16.4.1 Mexico
      16.4.2 Brazil
      16.4.3 Rest of the World
16.5 Rest of the World Oncology Biosimilars Market Value Share, by Drug Class, 2017 and 2025
16.6 Rest of the World Oncology Biosimilars Market Attractiveness, by Drug Class, 2017–2025
16.7 Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
      16.7.1 G-CSF
      16.7.2 Monoclonal Antibody
      16.7.3 Hematopoietic Agents
16.8 Rest of the World Oncology Biosimilars Market Value Share, by Disease Indication, 2017 and 2025
16.9 Rest of the World Oncology Biosimilars Market Attractiveness, by Disease Indication, 2017–2025
16.10 Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
      16.10.1 Breast Cancer
      16.10.2 Non-Small Cell lung Cancer
      16.10.3 Blood Cancer
                16.10.3.1 Leukemia
                          16.10.3.1.1 Myeloid Leukemia
                          16.10.3.1.2 Chronic Lymphocytic Leukemia
                          16.10.3.1.3 Others
                16.10.3.2 Non-Hodgkin Lymphoma
      16.10.4 Colorectal Cancer
      16.10.5 Neutropenia
      16.10.6 Others
16.11 Rest of the World Oncology Biosimilars Market Value Share, by Distribution Channel, 2017 and 2025
16.12 Rest of the World Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2017–2025
16.13 Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
      16.13.1 Hospital Pharmacy
      16.13.2 Online Pharmacy
      16.13.3 Retail Pharmacy
16.14 Key Trends

Section 17 Competition Landscape
17.1 Market Player – Competition Matrix (By Tier and Size of companies)
17.2 Market Share Analysis By Company (2016)

Section 18 Company Profiles
18.1 Sandoz International GmbH
      18.1.1 Company Details
      18.1.2 Business Overview
      18.1.3 Financial Overview
      18.1.4 Strategic Overview
      18.1.5 SWOT Analysis
18.2 Pfizer, Inc.
      18.2.1 Company Details
      18.2.2 Business Overview
      18.2.3 Financial Overview
      18.2.4 Strategic Overview
      18.2.5 SWOT Analysis
18.3 Celltrion Inc.
      18.3.1 Company Details
      18.3.2 Business Overview
      18.3.3 Financial Overview
      18.3.4 Strategic Overview
      18.3.5 SWOT Analysis
18.4 Dr. Reddy’s Laboratories Ltd.
      18.4.1 Company Details
      18.4.2 Business Overview
      18.4.3 Financial Overview
      18.4.4 Strategic Overview
      18.4.5 SWOT Analysis
18.5 Biocon
      18.5.1 Company Details
      18.5.2 Business Overview
      18.5.3 Financial Overview
      18.5.4 Strategic Overview
      18.5.5 SWOT Analysis
18.6 Teva Pharmaceutical Industries Ltd.
      18.6.1 Company Details
      18.6.2 Business Overview
      18.6.3 Financial Overview
      18.6.4 Strategic Overview
      18.6.5 SWOT Analysis
18.7 STADA Arzneimittel AG
      18.7.1 Company Details
      18.7.2 Business Overview
      18.7.3 Financial Overview
      18.7.4 Strategic Overview
      18.7.5 SWOT Analysis
18.8 Apotex Inc. (Apobiologix)
      18.8.1 Company Details
      18.8.2 Business Overview
      18.8.3 Financial Overview
      18.8.4 Strategic Overview
      18.8.5 SWOT Analysis
18.9 Intas Pharmaceuticals Ltd.
      18.9.1 Company Details
      18.9.2 Business Overview
      18.9.3 Financial Overview
      18.9.4 Strategic Overview
      18.9.5 SWOT Analysis
18.10 BIOCAD
      18.10.1 Company Details
      18.10.2 Business Overview
      18.10.3 Financial Overview
      18.10.4 Strategic Overview
      18.10.5 SWOT Analysis

List of Tables

Table 01 Global Biosimilars Market Snapshot
Table 02 Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 03 Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 04 Global Oncology Biosimilars Market Size (US$ Mn) Forecast, Blood Cancer, 2015–2025
Table 05 Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Leukemia, 2015–2025
Table 06 Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 07 Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 08 Approved Oncology Biosimilars by USFDA in new biosimilars pathway established under BPCIA Act
Table 09 North America Oncology Biosimilars: Pipeline Overview, 2017-2020
Table 10 North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 11 North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 12 Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 13 Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 14 Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 15 Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Blood Cancer, 2015–2025
Table 16 Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Leukemia, 2015–2025
Table 17 Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 18 Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 19 Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 20 Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 21 Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Blood Cancer, 2015–2025
Table 22 Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Leukemia, 2015–2025
Table 23 Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 24 Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 25 Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, Drug Class, 2015–2025
Table 26 Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 27 Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Blood Cancer, 2015–2025
Table 28 Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Leukemia, 2015–2025
Table 29 Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025

List of Figures


Fig. 01 Global Oncology Biosimilars Market Size (US$ Mn) Forecast, 2015–2025

Fig. 02 Global Oncology Biosimilars Market Value Share, by Drug Class (2016)

Fig. 03 Global Oncology Biosimilars Market Value Share, by Disease Indication (2016)

Fig. 04 Global Oncology Biosimilars Market Value Share, by Distribution Channel (2016)

Fig. 05 Global Oncology Biosimilars Market Value Share, by Region (2016)

Fig. 06 U.S. Prevalence Share (%), By Cancer Type, 2015

Fig. 07 Global Estimation of Cancer, By New Cases & Deaths, 2017 

Fig. 08 Global Oncology Biosimilars Market Value Share, by Drug Class, 2017 and 2025

Fig. 09 Global Oncology Biosimilars Market Attractiveness, by Drug Class, 2017–2025

Fig. 10 Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Monoclonal Antibody, 2015–2025

Fig. 11 Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Hematopoietic Agents, 2015–2025

Fig. 12 Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by G-CSF, 2015–2025

Fig. 13 Global Oncology Biosimilars Market Value Share, by Disease Indication, 2017 and 2025

Fig. 14 Global Oncology Biosimilars Market Attractiveness, by Disease Indication, 2017–2025

Fig. 15 Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Breast Cancer, 2015–2025

Fig. 16 Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Non-small Cell Lung Cancer, 2015–2025

Fig. 17 Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Blood Cancer, 2015–2025

Fig. 18 Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Colorectal Cancer, 2015–2025

Fig. 19 Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Neutropenia, 2015–2025

Fig. 20 Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Others, 2015–2025

Fig. 21 Global Oncology Biosimilars Market Value Share, by Distribution Channel, 2017 and 2025

Fig. 22 Global Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2017–2025

Fig. 23 Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Online Pharmacy, 2015–2025

Fig. 24 Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Retail Pharmacy, 2015–2025

Fig. 25 Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Hospital Pharmacy, 2015–2025

Fig. 26 Global Oncology Biosimilars Market Value Share, by Region, 2017 and 2025 

Fig. 27 Global Oncology Biosimilars Market Attractiveness, by Region, 2017–2025

Fig. 28 North America Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015–2025

Fig. 29 North America Oncology Biosimilars Market Value Share, by Country, 2017 and 2025 

Fig. 30 North America Oncology Biosimilars Market Attractiveness, by Country, 2017–2025

Fig. 31 North America Oncology Biosimilars Market Value Share, by Distribution Channel, 2017 and 2025

Fig. 32 North America Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2017–2025

Fig. 33 Europe Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015–2025

Fig. 34 Europe Oncology Biosimilars Market Value Share, by Country, 2017 and 2025 

Fig. 35 Europe Oncology Biosimilars Market Attractiveness, by Country, 2017–2025

Fig. 36 Europe Oncology Biosimilars Market Value Share, by Drug Class, 2017 and 2025

Fig. 37 Europe Oncology Biosimilars Market Attractiveness, by Drug Class, 2017–2025

Fig. 38 Europe Oncology Biosimilars Market Value Share, by Disease Indication, 2017 and 2025

Fig. 39 Europe Oncology Biosimilars Market Attractiveness, by Disease Indication, 2017–2025

Fig. 40 Europe Oncology Biosimilars Market Value Share, by Distribution Channel, 2017 and 2025

Fig. 41 Europe Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2017–2025

Fig. 42 Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025

Fig. 43 Asia Pacific Oncology Biosimilars Market Value Share, by Country, 2017 and 2025 

Fig. 44 Asia Pacific Oncology Biosimilars, Market Attractiveness, by Country, 2017–2025

Fig. 45 Asia Pacific Oncology Biosimilars Market Value Share, by Drug Class, 2017 and 2025

Fig. 46 Asia Pacific Oncology Biosimilars Market Attractiveness, by Drug Class, 2017–2025

Fig. 47 Asia Pacific Oncology Biosimilars Market Value Share, by Disease Indication, 2017 and 2025

Fig. 48 Asia Pacific Oncology Biosimilars Market Attractiveness, by Disease Indication, 2017–2025

Fig. 49 Asia Pacific Oncology Biosimilars Market Value Share, by Distribution Channel, 2017 and 2025

Fig. 50 Asia Pacific Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2017–2025

Fig. 51 Rest of the World Oncology Biosimilars, Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025

Fig. 52 Rest of the World Oncology Biosimilars Market Value Share, by Country, 2017 and 2025 

Fig. 53 Rest of the World Oncology Biosimilars, Market Attractiveness, by Country, 2017–2025

Fig. 54 Rest of the World Oncology Biosimilars Market Value Share, by Drug Class, 2017 and 2025

Fig. 55 Rest of the World Oncology Biosimilars Market Attractiveness, by Drug Class, 2017–2025

Fig. 56 Rest of the World Oncology Biosimilars Market Value Share, by Disease Indication, 2017 and 2025

Fig. 57 Rest of the World Oncology Biosimilars Market Attractiveness, by Disease Indication, 2017–2025

Fig. 58 Rest of the World Oncology Biosimilars Market Value Share, by Distribution Channel, 2017 and 2025

Fig. 59 Rest of the World Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2017–2025

Fig. 60 Global Oncology Biosimilars Market Share, by Company, 2016 

Fig. 61 Breakdown of Net Sales of Sandoz International GmbH (A Novartis Division), by Franchise, 2016 (%)

Fig. 62 Revenue (US$ Bn) & Y-o-Y Growth (%) of Sandoz International GmbH (A Novartis Division), 2013–2016

Fig. 63 Breakdown of Net Sales of Pfizer, Inc., by Region, 2016 (%)

Fig. 64 Revenue (US$ Bn) & Y-o-Y Growth (%) of Pfizer, Inc., 2013–2016

Fig. 65 Breakdown of Net Sales of Celltrion Inc., by Business Segments , 2016

Fig. 66 Revenue (US$ Mn) & Y-o-Y Growth (%) of Celltrion Inc., 2013–2016

Fig. 67 Breakdown of Net Sales of Dr. Reddy’s Laboratories Ltd., by Business Segments, 2016 (%)

Fig. 68 Revenue (US$ Bn) & Y-o-Y Growth (%) of Dr. Reddy’s Laboratories Ltd., 2013–2016

Fig. 69 Breakdown of Net Sales of Biocon, by Business Segments, 2016 (%)

Fig. 70 Revenue (US$ Mn) & Y-o-Y Growth (%) of Biocon, 2013–2016

Fig. 71 Breakdown of Net Sales of Teva Pharmaceutical Industries Ltd., by Business Segments, 2016 (%)

Fig. 72 Revenue (US$ Bn) & Y-o-Y Growth (%) of Teva Pharmaceutical Industries Ltd., 2013–2016

Fig. 73 Breakdown of Net Sales of STADA Arzneimittel AG, by Business Segments, 2016 (%)

Fig. 74 Revenue (US$ Bn) & Y-o-Y Growth (%) of STADA Arzneimittel AG, 2013–2016

Fig. 75 Revenue (US$ Mn) & Y-o-Y Growth (%) of Intas Pharmaceuticals Ltd., 2013–2016

Transparency Market Research Plus

Get a free copy if the report you purchased is updated within 90 days

Copyright © Transparency Market Research, Inc. All Rights reserved